- Home
- OUST vs ELVN Comparison
OUST vs ELVN Comparison
Compare OUST & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OUST
- ELVN
- Stock Information
- Founded
- OUST 2015
- ELVN 2016
- Country
- OUST United States
- ELVN United States
- Employees
- OUST N/A
- ELVN N/A
- Industry
- OUST Industrial Machinery/Components
- ELVN Biotechnology: Pharmaceutical Preparations
- Sector
- OUST Technology
- ELVN Health Care
- Exchange
- OUST Nasdaq
- ELVN Nasdaq
- Market Cap
- OUST 1.1B
- ELVN 1.1B
- IPO Year
- OUST N/A
- ELVN 2020
- Fundamental
- Price
- OUST $21.63
- ELVN $21.74
- Analyst Decision
- OUST Strong Buy
- ELVN Strong Buy
- Analyst Count
- OUST 6
- ELVN 5
- Target Price
- OUST $31.33
- ELVN $41.20
- AVG Volume (30 Days)
- OUST 2.8M
- ELVN 624.5K
- Earning Date
- OUST 11-04-2025
- ELVN 11-12-2025
- Dividend Yield
- OUST N/A
- ELVN N/A
- EPS Growth
- OUST N/A
- ELVN N/A
- EPS
- OUST N/A
- ELVN N/A
- Revenue
- OUST $137,298,000.00
- ELVN N/A
- Revenue This Year
- OUST $33.30
- ELVN N/A
- Revenue Next Year
- OUST $36.50
- ELVN $20.05
- P/E Ratio
- OUST N/A
- ELVN N/A
- Revenue Growth
- OUST 30.20
- ELVN N/A
- 52 Week Low
- OUST $6.34
- ELVN $13.30
- 52 Week High
- OUST $41.65
- ELVN $25.96
- Technical
- Relative Strength Index (RSI)
- OUST 38.85
- ELVN 53.99
- Support Level
- OUST $18.52
- ELVN $20.37
- Resistance Level
- OUST $22.49
- ELVN $22.85
- Average True Range (ATR)
- OUST 1.97
- ELVN 1.37
- MACD
- OUST -0.25
- ELVN 0.15
- Stochastic Oscillator
- OUST 37.26
- ELVN 73.89
About OUST Ouster Inc.
Ouster Inc is a provider of lidar sensors for the automotive, industrial, robotics, and smart infrastructure industries. Ouster's products include high-resolution scanning and solid-state digital lidar sensors, Velodyne Lidar sensors, and software solutions. The company operates in the Americas, Asia and Pacific, Europe, Middle East, and Africa regions. It derives maximum revenue from Americas.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.